Johannes Gerardus Chri Schikan Sells 30,712 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares in the company, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $241,424.40.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total value of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Trading Down 1.8%

Shares of NASDAQ:PHVS traded down $0.63 during trading on Wednesday, reaching $33.95. 376,128 shares of the company traded hands, compared to its average volume of 409,202. Pharvaris N.V. has a 52-week low of $17.05 and a 52-week high of $35.90. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -10.68 and a beta of -2.34. The business’s fifty day moving average is $30.90 and its 200-day moving average is $28.21.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. On average, sell-side analysts predict that Pharvaris N.V. will post -3.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Large investors have recently bought and sold shares of the business. General Atlantic L.P. lifted its holdings in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC raised its stake in shares of Pharvaris by 8.3% in the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC boosted its stake in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. raised its position in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares during the period. Finally, Commodore Capital LP lifted its stake in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently weighed in on PHVS shares. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Citizens Jmp reduced their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Morgan Stanley increased their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. Finally, UBS Group set a $74.00 price target on shares of Pharvaris in a report on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.64.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.